Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748813 | 1.00 | MEN1 (0.55) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL21444905 | 0.96 | MEN1 (0.50) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL29576686 | 0.90 | MEN1 (0.52) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL21323141 | 0.90 | MEN1 (0.50) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL18811650 | 0.89 | MEN1 (0.47) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL10190373 | 0.88 | MEN1 (0.57) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL16862524 | 0.88 | MEN1 (0.57) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL23629902 | 0.87 | MEN1 (0.44) | MEN1KMT2AGAAC3AR1MAOA | |
| SCHEMBL31075715 | 0.85 | CTSS (0.43) | MEN1KMT2AGAAC3AR1CTSS | |
| SCHEMBL23629909 | 0.85 | CTSS (0.43) | MEN1KMT2AGAAC3AR1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3408271-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-10624968-B2 | Compounds for treating cancer | Bicyclerd Limited (GB) | 2020-04-21 | — | — | US | disclosed |
| EP-3607996-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| EP-3498301-A1 | KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-06-19 | — | — | EP | disclosed |
| EP-3134124-B1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624968-B2 | Compounds for treating cancer | TP53, VHL, MYC | MEN1 900/4885KMT2A 619/4885GAA 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.